Skip to main content
SpringerLink
Log in

Expanded phase II trial of paclitaxel in metastatic breast cancer: A Southwest Oncology Group study

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Background. The study was designed to evaluate the efficacy of paclitaxel in metastatic breast cancer patients. The design was motivated by a report from FDA and NCI staff proposing assessment of pre- and post-treatment symptoms as a means of evaluating treatment effectiveness [1]. Methods. Patients with symptomatic and/or measurable metastatic breast cancer with prior treatment received paclitaxel 210 mg/m2 as a 3 hour infusion every three weeks until toxicity or progression. A unique endpoint was subjective symptomatic response, defined as an improvement in the Symptom Distress Scale score by ≥ 3 points at two successive evaluations before treatment failure. Patients were also evaluated for objective response and toxicity. Results. Of 135 patients registered, 123 were eligible and treated. The subjective symptomatic response rate for 93 symptomatic patients who completed forms was 40%, 95% confidence interval 29–51%. The objective response rate in 77 patients with measurable disease was 19%, 95% confidence interval 11–30%. In patients with both measurable and symptomatic disease, 37% had symptomatic and 13% had objective responses. Median times to treatment failure and death were 4 and 11 months, respectively. Toxicity was greater than anticipated: 12% discontinued treatment due to toxicity, 29% developed at least one Grade 3 neuromuscular toxicity, and two patients died of sepsis while neutropenic. Conclusion. Paclitaxel by 3 hour infusion at a dose of 210 mg/m2 produced excessive neurotoxicity in patients with previously treated metastatic breast cancer. Both sustained subjective symptom reduction and objective responses were demonstrated, but dose reduction for routine practice is recommended.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. O'Shaughnessy JA, Wittes RE, Burke G, et al.: Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials. J Clin Oncol 9: 2225–2231, 1991

    Google Scholar 

  2. Henderson IC: Chemotherapy for metastatic disease In: Harris JR, Hellman S, Henderson IC, Kinne DW (eds) Breast Diseases (ed 2). Lippincott, Philadelphia, PA, 1991, pp 628–630

    Google Scholar 

  3. Holmes FA, Walters RS, Theriault RL, et al.: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797–1805, 1991

    Google Scholar 

  4. Reichman B, Seidman A, Crown J, et al.: Paclitaxel and to combinant human granulocyte colony-stimulating factor as initial therapy for metastatic breast cancer. J Clin Oncol 10: 1943–1951, 1993

    Google Scholar 

  5. Rowinsky EK, Donehower RC: Paclitaxel (Taxol®). N Engl J Med 332: 1004–1014, 1995

    Google Scholar 

  6. Swenerton K, Eisenhauer E, Huinink WT, et al.: Taxol in relapsed ovarian cancer. High vs low dose and short vs long infusion. Proc Am Soc Clin Oncol 12: 256, 1993 (abst 810)

    Google Scholar 

  7. Nabholtz JM, Gelmon K, Bontenbal M, et al.: Randomized trial of two doses of taxol in metastatic breast cancer: An interim analysis. Proc Am Soc Clin Oncol 12: 60, 1993 (abst 42)

    Google Scholar 

  8. Postma TJ, Liefting AJM, Heimans JJ, et al.: Neurotoxicity in patients with breast cancer and ovarian cancer treated with taxol. Proc Am Soc Clin Oncol 12: 64, 1993, abstract 56

    Google Scholar 

  9. McCorkle R, Young K: Development of symptom distress scale. Cancer Nurs 1: 373–378, 1978

    Google Scholar 

  10. McCorkle R, Benoliel JO: Symptom distress, current concerns and mood disturbance after diagnosis of life-threatening disease. Soc Sci Med 17: 431–438, 1983

    Google Scholar 

  11. McCorkle R, Benoliel JO, Donaldson G, Goodell B: Evaluation of cancer management. Final report of project NU 01001. Supported by the Division of Nursing. Bureau of Health Professions, Health Resources and Services Administration, U.S. Public Health Service, 1986

  12. McCorkle R, Benoliel JO, Donaldson G, et al.: A randomized clinical trial of home nursing care for lung cancer patients. Cancer 64: 1375–1382, 1989

    Google Scholar 

  13. McCorkle R: The measurement of symptom distress. Semin Oncol Nurs 3: 248–256, 1987

    Google Scholar 

  14. Young KJ, Longman AJ: Quality of life and persons with melanoma: A pilot study. Cancer Nurs 6: 219–225, 1983

    Google Scholar 

  15. Cohen J: Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale NJ: Lawrence Erlbaum Associates, Publishers, 1988

    Google Scholar 

  16. Degner LF, Sloan J: Symptom distress in newly diagnosed cancer patients and as a predictor of survival in lung cancer. J Pain Symptom Management 10: 423–431, 1995

    Google Scholar 

  17. Northouse LL, Laten D, Reddy P: Adjustment of women and their husbands to recurrent breast cancer. Res Nurs Health 18: 515–524, 1995

    Google Scholar 

  18. Pasacreta JV: Depressive phenomena, physical symptom distress and functional status among women with breast cancer. Nurs Res (in press)

  19. Samarel N, Fawcett J, Tuonan L: The effects of coaching in breast cancer support groups: A pilot study. Oncol Nurs Forum 20: 795–798, 1993

    Google Scholar 

  20. Green SJ, Weiss G: SWOG standard response, criteria end-point definition and toxicity criteria. IND 10: 239–253, 1992

    Google Scholar 

  21. Cronbach LJ: Coefficient alpha and the internal structure of tests. Psychometrika 16: 297–334, 1951

    Google Scholar 

  22. Howell A, Mackintosh J, Jones M, et al.: The definition of the ‘no change’ category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Clin Oncol 24: 1567–1572, 1988

    Google Scholar 

  23. Gianni L, Munzone E, Capri G, et al.: Paclitaxel in metastatic breast cancer: A trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 87: 1169–1174, 1995

    Google Scholar 

  24. Nabholtz JM, Gelmon K, Bontenbal M, et al.: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14: 1858–1866, 1996

    Google Scholar 

  25. Seidman AD, Tiersten A, Hudis C, et al.: Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 13: 2575–2581, 1995

    Google Scholar 

  26. Weiner E, Berry D, Duggan D, et al.: Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer — Results from CALGB 9342. Proc Am Soc Clin Oncol 17: 101a, 1998, abstract 388

    Google Scholar 

  27. Peretz T, Sulkes A, Chollet P, et al.: A multicenter randomized study of two schedules of paclitaxel in patients with advanced breast cancer. Eur J Cancer 31A(suppl 5): S75, 1995, abstract 345

    Google Scholar 

  28. Mamounas T, Brown A, Smith R, et al.: Effect of taxol duration of infusion in advanced breast cancer (ABC): Results from NSABP B-26 trial comparing 3-to 24-hr infusion of high-dose taxol. Proc Am Soc Clin Oncol 17: 101a, 1998, abstract 389

    Google Scholar 

  29. Holmes FA, Valero V, Buzdar AV, et al.: Final results: Randomized phase III trial of paclitaxel by 3-hr versus 96-hr infusion in patients with metastatic breast cancer. The long and short of it. Proc Am Soc Clin Oncol 17: 110a, 1998. abstract 426

    Google Scholar 

  30. Asbury R, Chang A, Burroughs L, et al.: Weekly moderate dose paclitaxel in advanced breast cancer. Proc Am Soc Clin Oncol 17: 127a, 1998, abstract 486

    Google Scholar 

  31. Breier S, Lebedinsky C, Ayiviri C, et al.: Long-term weekly paclitaxel in metastatic breast cancer. A phase II trial in pretreated patients. Proc Am Soc Clin Oncol 17: 192a, 1998, abstract 740

    Google Scholar 

  32. Testa MA, Simonson DC: Assessment of quality-of-life outcomes. N Engl J Med 334: 835–840, 1996

    Google Scholar 

  33. Scidman AD, Portenoy R, Yao TJ, et al.: Quality of life in phase II trials: A study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor, J Natl Cancer Inst 87: 1316–1322, 1995

    Google Scholar 

  34. Moinpour CM, Feigl P. Metch B, et al.: Quality of life end points in cancer clinical trials: Review and recommendations. J Natl Cancer Inst 85: 485–495, 1989

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Joe Arrington Cancer Center, Lubbock, TX

    Charles E. Geyer Jr.

  2. Southwest Oncology Group Statistical Center, Seattle, WA

    Stephanie J. Green, Carol M. Moinpour & Janet O'Sullivan

  3. Scott & White Clinic, Temple, TX

    Donna K. Goodwin

  4. University of Oklahoma Health Science Center, Oklahoma City, OK

    Vikki A. Canfield

  5. University of California at Davis, Sacramento, CA

    Frederick J. Meyers

  6. University of Texas Health Science Center at San Antonio, San Antonio, TX

    C. Kent Osborne

  7. Van Nuys Breast Center, Van Nuys, CA, USA

    Silvana Martino

Authors
  1. Charles E. Geyer Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephanie J. Green
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carol M. Moinpour
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Janet O'Sullivan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Donna K. Goodwin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Vikki A. Canfield
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Frederick J. Meyers
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C. Kent Osborne
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Silvana Martino
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Geyer, C.E., Green, S.J., Moinpour, C.M. et al. Expanded phase II trial of paclitaxel in metastatic breast cancer: A Southwest Oncology Group study. Breast Cancer Res Treat 51, 169–181 (1998). https://doi.org/10.1023/A:1006094403153

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006094403153

Search

Navigation